MC
CRSP icon

Moors & Cabot’s CRISPR Therapeutics CRSP Stock Holding History

Moors & Cabot’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,200
Closed -$5.16K – 928
2023
Q4 		$5.16K Buy
+1,200
New +$66.3K ﹤0.01% 831
2021
Q3 		– Sell
-2,100
Closed -$32K – 876
2021
Q2 		$32K Buy
2,100
+1,700
+425% +$207K ﹤0.01% 797
2021
Q1 		$11K Buy
+400
New +$60.4K ﹤0.01% 754

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Moors & Cabot's CRSP Position: Q1 2026 in Review

Moors & Cabot reduced its CRISPR Therapeutics (CRSP) stake by 1.8% in Q1 2026, selling an estimated $4.75K and leaving 4,957 shares worth $236K. The position accounts for 0.01% of the portfolio, ranked #805.

Moors & Cabot first reported a position in CRSP in Q1 2021 and has held it in 9 quarters since. The position peaked at $334K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Moors & Cabot held 4,957 shares of CRISPR Therapeutics worth $236K as of Q1 2026.
  • Moors & Cabot sold 90 CRISPR Therapeutics shares in Q1 2026, an estimated $4.75K.
  • CRISPR Therapeutics made up 0.01% of Moors & Cabot's portfolio in Q1 2026, its #805 holding.
  • Moors & Cabot first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • Moors & Cabot's CRISPR Therapeutics position peaked at $334K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.